DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

Consistently reported prognostic factors for glioblastoma (GBM) are age, extent of surgery, performance status, IDH1 mutational status, and MGMT promoter methylation status. We aimed to integrate biological and clinical prognostic factors into a nomogram intended to predict the survival time of an i...

Full description

Bibliographic Details
Main Authors: Amandine Etcheverry, Marc Aubry, Ahmed Idbaih, Elodie Vauleon, Yannick Marie, Philippe Menei, Rachel Boniface, Dominique Figarella-Branger, Lucie Karayan-Tapon, Veronique Quillien, Marc Sanson, Marie de Tayrac, Jean-Yves Delattre, Jean Mosser
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4169423?pdf=render

Internet

http://europepmc.org/articles/PMC4169423?pdf=render

Similar Items